Clinical trialPhase 2Recruiting
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of IBI343 in Combination Therapy for Patients With Advanced Malignant Solid Tumors.
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 20 April 2026
- Expected end
- 31 March 2028
- Enrollment
- 389 participants
- Sites
- 1
- Primary outcomes
- Objective Response Rate (ORR) evaluated according to RECIST v1.1; Incidence of Adverse Events (AE); Incidence of treatment-emergent adverse Events (TEAE); Incidence of adverse events of Special Interest (AESI); Incidence of serious adverse events (SAE)
- Sponsor
- Industry
- Results posted
- No
- Last update
- 3 June 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid tumors.Enrollment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma positive for CLDN18.2, and subjects with pancreatic ductal adenocarcinoma positive for CLDN18.2.